POEMS Syndrome
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Cell Therapy
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UNION therapeuticsDenmark - Hellerup
1 program1
Lenalidomide, DexamethasonePhase 21 trial
Active Trials
Novatim Immune TherapeuticsChina - Shanghai
1 program1
KQ-2003 CAR T-cellsPhase 1Cell Therapy1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
UNION therapeuticsLenalidomide, Dexamethasone
Novatim Immune TherapeuticsKQ-2003 CAR T-cells
Clinical Trials (2)
Total enrollment: 62 patients across 2 trials
Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
Start: Mar 2014Est. completion: Apr 201741 patients
Phase 2Completed
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
Start: Aug 2024Est. completion: Dec 202721 patients
Phase 1Not Yet Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Cell Therapy is the dominant modality (100% of programs)
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.